Table 4.

Odds ratios of developing myalgia in the JUPITER trial

Variables	β	Odds ratio 95% confidence interval	P-value
Main effects model
Asp247Asp vs. 247GlyX Gly247X	0.16	1.17 (1.02–1.35)	0.03
Adjusted model
Asp247Asp vs. 247GlyX	0.30	1.35 (1.07–1.71)	0.01
Rosuvastatin vs. placebo	−0.13	0.88 (0.68–1.13)	0.34
Final CK measure (log transformed)	0.19	1.21 (0.87–1.69)	0.26
Asp247Gly*rosuvastatin	−0.34	0.71 (0.51–0.99)	0.04

The adjusted model accounts for treatment allocation arm and final CK measures.

CK, creatine phosphokinase.